Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Current Status of Oncothermia Therapy for Lung Cancer

  • Szasz, Andras (Department of Biotechnics, St. Istvan University)
  • Received : 2014.02.28
  • Accepted : 2014.03.28
  • Published : 2014.04.05
Download PDF
⟨ Previous Next ⟩

Abstract

Lung cancer is one of the most common malignant tumors, and it has the highest death rate. Oncothermia is a feasible and successful treatment for lung cancer. Results show a remarkable survival benefit for patients, with a good quality of life. The treatment has no, or in some cases mild, side-effects and could decrease the adverse effects of the complementary treatment. Applying oncothermia together with other treatment methods could increase the effects and result in better performance. A comparison of studies demonstrates a good correspondence in the data, which strengthens the reliability of the studies, and clearly shows the feasibility of the application of oncothermia to treating all kinds of pulmonary malignancies including non-small-cell and small-cell primary tumors, and all of the metastatic diseases of the pulmonary system.

Keywords

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30. https://doi.org/10.3322/caac.21166
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. https://doi.org/10.3322/CA.2007.0010
  3. Cancer Research UK. Ten-year predicted survival estimates were provided by the Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine on request, December [Internet]. Oxford: Cancer Research UK; 2012 [cited 2014 Feb 20]. Available from: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/lung/survival/lung-cancer-survival-statistics#source2.
  4. Haura EB. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 2001;8: 326-36.
  5. Ries LA, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2000 [Internet]. Bethesda (MD): National Cancer Institute; 2003 [cited 2003 Apr 29]. Available from: http://seer.cancer.gov/csr/1975_2000.
  6. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci 2010;25:1113-21. https://doi.org/10.3346/jkms.2010.25.8.1113
  7. Jung KW, Won YJ, Park S, et al. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 2009;24:995-1003. https://doi.org/10.3346/jkms.2009.24.6.995
  8. Jin G, Jeon HS, Lee EB, et al. EML4-ALK fusion gene in Korean non-small cell lung cancer. J Korean Med Sci 2012; 27:228-30. https://doi.org/10.3346/jkms.2012.27.2.228
  9. Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Changes in the natural history of nonsmall cell lung cancer (NSCLC): comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 2006;106:2208-17. https://doi.org/10.1002/cncr.21869
  10. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-62. https://doi.org/10.1378/chest.128.1.452
  11. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24: 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
  12. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909. https://doi.org/10.1136/bmj.311.7010.899
  13. Natale RB. Gemcitabine-based doublets for advanced nonsmall- cell lung cancer: beyond gemcitabine/cisplatin. Clin Lung Cancer 2002;3 Suppl 1:S10-6. https://doi.org/10.3816/CLC.2002.s.002
  14. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. https://doi.org/10.1056/NEJMoa011954
  15. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97. https://doi.org/10.1200/JCO.2004.08.163
  16. Roy M, Luo YH, Ye M, Liu J. Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors. Biomed Res Int 2013;2013:964743.
  17. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. https://doi.org/10.1126/science.1141478
  18. Ganti AK, West WW, Zhen W. Current concepts in the management of small cell lung cancer. Indian J Med Res 2013;137:1043-51.
  19. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33-56. https://doi.org/10.1016/S1040-8428(01)00179-2
  20. Jiang Z, Yan W, Ming J, Yu Y. Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study. BMC Cancer 2007;7:189. https://doi.org/10.1186/1471-2407-7-189
  21. Shen H, Li XD, Wu CP, Yin YM, Wang RS, Shu YQ. The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: a phase II study. Int J Hyperthermia 2011;27:27-32. https://doi.org/10.3109/02656736.2010.500645
  22. Moon SD, Ohguri T, Imada H, et al. Definitive radiotherapy plus regional hyperthermia with or without chemotherapy for superior sulcus tumors: a 20-year, single center experience. Lung Cancer 2011;71:338-43. https://doi.org/10.1016/j.lungcan.2010.06.007
  23. Sumiyoshi K, Strebel FR, Rowe RW, Bull JM. The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases. Int J Hyperthermia 2003;19:103-18. https://doi.org/10.1080/0265673021000017091
  24. Hermisson M, Weller M. Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Res 2000;20:1819-23.
  25. Hiraoka M, Masunaga S, Nishimura Y, et al. Regional hyperthermia combined with radiotherapy in the treatment of lung cancers. Int J Radiat Oncol Biol Phys 1992;22:1009-14. https://doi.org/10.1016/0360-3016(92)90800-W
  26. Imada H, Nomoto S, Tomimatsu A, et al. Local control of nonsmall cell lung cancer by radiotherapy combined with high-power hyperthermia using 8 MHz RF capacitive heating device. Jpn J Hyperthermic Oncol 1999;15:19-24.
  27. Karasawa K, Muta N, Nakagawa K, et al. Thermoradiotherapy in the treatment of locally advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1994;30:1171-7. https://doi.org/10.1016/0360-3016(94)90325-5
  28. Sakurai H, Hayakawa K, Mitsuhashi N, et al. Effect of hyperthermia combined with external radiation therapy in primary non-small cell lung cancer with direct bony invasion. Int J Hyperthermia 2002;18:472-83. https://doi.org/10.1080/02656730210146917
  29. Sakao S, Takiguchi Y, Nemoto K, et al. Thermoradiotherapy for local control of chest wall invasion in patients with advanced non-small cell lung cancer. Int J Clin Oncol 2002;7: 343-8. https://doi.org/10.1007/s101470200052
  30. Hettinga JV, Lemstra W, Meijer C, et al. Hyperthermic potentiation of cisplatin toxicity in a human small cell lung carcinoma cell line and a cisplatin resistant subline. Int J Hyperthermia 1994;10:795-805. https://doi.org/10.3109/02656739409012372
  31. Higashiyama M, Doi O, Kodama K, Yokouchi H. Intrathoracic chemothermotherapy following panpleuropneumonectomy for pleural dissemination of invasive thymoma. Chest 1994;105:1884-5. https://doi.org/10.1378/chest.105.6.1884
  32. Doi O, Kodama K, Higashiyama M, Kuriyama K, Tateishi R. Postoperative chemothermotherapy fo locally advanced lung cancer with carcinomatous pleuritis. In: Matsuda T, editor. Cancer treatment by hyperthermia, radiation, and drugs. London: Taylor & Francis; 1993. p. 338-52.
  33. Yang H, Jiang G, Fu X, Liao J. Radiotherapy and hyperthermia for NSCLC. ASCO Annual Meeting: no. 7289. Chicago: American Society of Clinical Oncology; 2005.
  34. Kodama K, Doi O, Higashiyama M, Yokouchi H, Tatsuta M. Long-term results of postoperative intrathoracic chemo- thermotherapy for lung cancer with pleural dissemination. Cancer 1993;72:426-31. https://doi.org/10.1002/1097-0142(19930715)72:2<426::AID-CNCR2820720218>3.0.CO;2-S
  35. Yang H, Jiang G, Fu X, et al. Radiotherapy and hyperthermia for NSCLC. ASCO Annual Meeting: no. 7289. Chicago: American Society of Clinical Oncology; 2005.
  36. Vertrees RA, Das GC, Popov VL, et al. Synergistic interaction of hyperthermia and Gemcitabine in lung cancer. Cancer Biol Ther 2005;4:1144-53. https://doi.org/10.4161/cbt.4.10.2074
  37. Shinn KS, Choi IB, Kim IA, Choi BO, Jang JY, Kay CS. Thermoradiotherapy in the treatment of locally advanced nonsmall cell lung cancer. J Korean Soc Ther Radiol 1996; 14:115-22.
  38. Vasanthan A, Mitsumori M, Park JH, et al. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys 2005;61:145-53. https://doi.org/10.1016/j.ijrobp.2004.04.057
  39. Mitsumori M, Zeng ZF, Oliynychenko P, et al. Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency. Int J Clin Oncol 2007;12:192-8. https://doi.org/10.1007/s10147-006-0647-5
  40. Yokoyama M, Nitta S. Systemic hyperthermia to patients with advanced pulmonary cancer. In: Matsuda T, editor. Cancer treatment by hyperthermia, radiation and drugs. London: Taylor & Francis; 1993. p. 376-81.
  41. Chhajed PN, Tamm M. Radiofrequency heat ablation for lung tumors: potential applications. Med Sci Monit 2003;9:ED5-7.
  42. Okuma T, Matsuoka T, Yamamoto A, et al. Factors contributing to cavitation after CT-guided percutaneous radiofrequency ablation for lung tumors. J Vasc Interv Radiol 2007;18:399-404. https://doi.org/10.1016/j.jvir.2007.01.004
  43. Weigel C, Kirsch M, Mensel B, Nerger U, Hosten N. Percutaneous laser-induced thermotherapy of lung metastases: experience gained during 4 years. Radiologe 2004;44:700-7.
  44. Matsuzaki Y, Edagawa M, Shimizu T, et al. Intrapleural hyperthermic perfusion with chemotherapy increases apoptosis in malignant pleuritis. Ann Thorac Surg 2004;78:1769-72. https://doi.org/10.1016/j.athoracsur.2004.05.025
  45. Sekins KM, Leeper DB, Hoffman JK, et al. Feasibility of lung cancer hyperthermia using breathable perfluorochemical (PFC) liquids. Part II: Ultrasound hyperthermia. Int J Hyperthermia 2004;20:278-99. https://doi.org/10.1080/02656730310001605528
  46. Szasz A, Szasz N, Szasz O. Oncothermia: principles and practices. London: Springer Verlag; 2010.
  47. Szasz A, Morita T. Heat therapy in oncology: oncothermia, new paradigm in hyperthermia. Tokyo: Nippon Gyorosha;2012.
  48. Andocs G, Szasz O, Szasz A. Oncothermia treatment of cancer: from the laboratory to clinic. Electromagn Biol Med 2009;28:148-65. https://doi.org/10.1080/15368370902724633
  49. Szasz O. Burden of oncothermia: why is it special? Conference Papers in Medicine: vol. 2013. Cairo: Hindawi Publishing Co.; 2013.
  50. Szasz A. Physical background and technical realization of hyperthermia. In: Baronzio GF, Hager ED, editors. Locoregional radiofrequency-, perfusional- and wholebody-hyperthermia in cancer treatment: new clinical aspects. New York: Springer; 2006. p. 27-59.
  51. Szasz A. Challenges and solutions in oncological hyperthermia. Thermal Med 2013;29:1-23. https://doi.org/10.3191/thermalmed.29.1
  52. Szasz A, Szasz N, Szasz O. Local hyperthermia in oncology. In: Huilgol N, editor. Hyperthermia. Rijeka: InTech; 2013.
  53. Andocs G, Renner H, Balogh L, Fonyad L, Jakab C, Szasz A. Strong synergy of heat and modulated electromagnetic field in tumor cell killing. Strahlenther Onkol 2009;185:120-6. https://doi.org/10.1007/s00066-009-1903-1
  54. Szasz O. Essentials of oncothermia. Conference Papers in Medicine: vol. 2013. Cairo: Hindawi Publishing Co.; 2013.
  55. Szasz A. Electromagnetic effects of nanoscale range. In: Shimizu T, Kondo T, editors. Cellular response to physical stress and therapeutic application. New York: Nova Biomedical;2013.
  56. Szasz O, Andocs G, Meggyeshazi N. Modulation effect in oncothermia. Conference Papers in Medicine: vol. 2013. Cairo: Hindawi Publishing Co.; 2013.
  57. Szasz O, Szasz N, Meggyeshazi N. Oncothermia as personalized treatment option. Conference Papers in Medicine: vol. 2013. Cairo: Hindawi Publishing Co.; 2013.
  58. Meggyeshazi N, Andocs G, Krenacs T. Programmed cell death induced by modulated electrohyperthermia. Conference Papers in Medicine: vol. 2013. Cairo: Hindawi Publishing Co.; 2013.
  59. Meggyeshazi N, Andocs G, Balogh L, et al. DNA fragmentation and caspase-independent programmed cell death by modulated electrohyperthermia. Strahlenther Onkol 2014 Feb 22 [Epub].
  60. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35:495-516. https://doi.org/10.1080/01926230701320337
  61. Meggyeshazi N, Krenacs T, Andocs G, Szasz O. Oncothermia in laboratory. Proceedings of the 32nd Conference of the International Clinical Hyperthermia Society; 2013 Nov 8-10; Guangzhou, China. [place unknown]: International Clinical Hyperthermia Society; 2013.
  62. Andocs G. Complex structure in oncothermia research and innovation. Proceedings of the International Hyperthermia Symposium; 2014 Feb 15; Jeju, Korea. [place unknown]: International Clinical Hyperthermia Society; 2014.
  63. Andocs G, Meggyeshazi N, Okamoto Y, Balogh L, Szasz O. Bystander effect of oncothermia. Conference Papers in Medicine: vol. 2013. Cairo: Hindawi Publishing Co.; 2013.
  64. Ahmed K, Zaidi SF. Treating cancer with heat: hyperthermia as promising strategy to enhance apoptosis. J Pak Med Assoc 2013;63:504-8.
  65. Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 2013;20:22-31.
  66. Kibble A, D'Souza P. Spotlight on... non-small-cell lung cancer: a new era in personalized care. New York: Thomson Reuters; 2013.
  67. Ahn JM, Cho JY. Current serum lung cancer biomarkers. J Mol Biomark Diagn 2013;S4:2.
  68. Haam SJ, Kim GD, Cho SH, Lee DY. Clinical effectiveness of tumor markers (CEA, NSE, Cyfra 21-1) in completely resected non-small cell lung cancer. J Lung Cancer 2006; 5:75-83. https://doi.org/10.6058/jlc.2006.5.2.75
  69. Oyama T, Osaki T, Baba T, et al. Molecular genetic tumor markers in non-small cell lung cancer. Anticancer Res 2005;25:1193-6.
  70. Stieber P, Hatz R, Holdenrieder S, et al. National Academy of Clinical Biochemistry guidelines for the use of tumor markers in lung cancer, section 3P. Basel: Roche Diagnostics;2008.
  71. Jeung TS, Ma SY, Yu S, Lim S. Cases that respond to oncothermia monotherapy. Conference Papers in Medicine: vol. 2013. Cairo: Hindawi Publishing Co.; 2013.
  72. Rubovszky G, Nagy T, Godeny M, Szasz A, Lang I. Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia. Pathol Oncol Res 2013;19:119-22. https://doi.org/10.1007/s12253-012-9551-7
  73. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. https://doi.org/10.1056/NEJMoa061884
  74. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-smallcell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34. https://doi.org/10.1200/JCO.2007.14.5466
  75. Laskin J, Crino L, Tsai C. MO19390 (SAIL): first-line bevacizumab- based therapy in advanced non-small cell lung cancer (NSCLC): outcome by chemotherapy regimen [abstract]. J Thorac Oncol 2009;4(Suppl 1):S359.
  76. Hirsh V. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. Clin Lung Cancer 2008;9 Suppl 2:S62-70. https://doi.org/10.3816/CLC.2008.s.010
  77. Crino L, Mezger J, Griesinger F, et al. MO19390 (SAIL): safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2009;27:417S.
  78. Fischbach N, Spigel D, Brahmer J; On Behalf of the ARIES Investigators. Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: a bevacizumab (BV) treatment observational cohort study (OCS) [abstract]. Proc Am Soc Clin Oncol 2009;27:416S.
  79. Mezger J, von Pawel J, Reck M. Bevacizumab (Bv) single- agent maintenance following Bv-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): results from an exploratory analysis of the AVAiL study [abstract]. Proc Am Soc Clin Oncol 2009;27:e19001.
  80. Miller V, O'Connor P, Soh C; On Behalf of the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2009;27:799S. https://doi.org/10.1200/JCO.2008.18.9670
  81. Yoon SM, Lee JS. Case of abscopal effect with metastatic non-small-cell lung cancer. Oncothermia J 2012;5:53-7.
  82. Min SG. Clinically complete remission of a disseminated non-small-cell lung cancer (NSCLC) case with oncothermia and concurrent 5th-line chemotherapy. Poster of the 31st International Clinical Hyperthermia Society Conference; 2012 Oct 12-14; Budapest, Hungary. [place unknown]: International Clinical Hyperthermia Society; 2012.
  83. Polo V, Besse B. Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? Ann Oncol 2013 Dec 18 [Epub].
  84. Lee DY, Park JS, Leem CY, et al. The outcomes of oncothermia with chemotherapy for far advanced lung cancer (3 cases of adenocarcinoma). Proceedings of the 32nd Conference of the International Clinical Hyperthermia Society; 2013 Nov 8-10; Guangzhou, China. [place unknown]: International Clinical Hyperthermia Society; 2013.
  85. Lee Y. Oncothermia application for various malignant diseases. Conference Papers in Medicine: vol. 2013. Cairo: Hindawi Publishing Co.; 2013.
  86. Kim JH, Kim DR. Mixed response to TS-1 and oncothermia in an esophageal cancer patient with lung metastases: case report. Poster at the 32nd Conference of the International Clinical Hyperthermia Society; 2013 Nov 8-10; Guangzhou, China. [place unknown]: International Clinical Hyperthermia Society; 2013.
  87. Lee CG. Definitive concurrent radio-oncothermia with or without chemotherapy in locally advanced non-small cell lung cancer: early clinical experience. Proceedings of the International Hyperthermia Symposium; 2014 Feb 15; Jeju, Korea. [place unknown]: International Clinical Hyperthermia Society; 2014.
  88. Zhao C. Evaluation the effect of local hyperthermia on late stage lung cancer patients. Proceedings of the 32nd Annual Conference of International Clinical Hyperthermia Society; 013 Nov 12-14; Guangzhou, China. [place unknown]: International Clinical Hyperthermia Society; 2013.
  89. Lee DY, Haam SJ, Kim TH, et al. Oncothermia with chemotherapy in the patients with small-cell lung cancer. Conference Papers in Medicine: vol. 2013. Cairo: Hindawi Publishing Co.; 2013.
  90. Dani A, Varkonyi A, Osvath M, Szasz A. Treatment of non-small-lung-cancer by electro-hyperthermia. Strahlenter Onko 2004;180:20.
  91. Dani A, Varkonyi A, Nyiro I, Osvath M. Clinical experience of electro-hyperthermia for advanced lung-tumors. Proceedings of the European Society of Hyperthermic Oncology Conference; 2003 Jun 4-7; Munich, Germany. Rotterdam: European Society of Hyperthermic Oncology; 2003.
  92. Hager ED, Krautgartner IH, Popa C, Hohmann D, Dziambor H. Deep hyperthermia with short waves of patients with advanced stage lung cancer, hyperthermia in clinical practice. XXII Meeting of International Clinical Hyperthermia Society. [place unknown]: International Clinical Hyperthermia Society;1999.
  93. Dani A, Varkonyi A, Magyar T, Szasz A. Clinical study for advanced non-small-cell lung-cancer treated by oncothermia. Forum Hyperthermie; 2010..

Cited by

  1. The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case Reports of Four Patients vol.4, pp.1, 2015, https://doi.org/10.4236/alc.2015.41001
  2. Definitive radiotherapy with concurrent oncothermia for stage IIIB non-small-cell lung cancer: A case report vol.10, pp.2, 2015, https://doi.org/10.3892/etm.2015.2567
  3. Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy vol.15, pp.None, 2014, https://doi.org/10.1186/s12885-015-1690-2
  4. Effect of Modulated Electrohyperthermia on the Pharmacokinetics of Oral Transmucosal Fentanyl Citrate in Healthy Volunteers vol.38, pp.12, 2014, https://doi.org/10.1016/j.clinthera.2016.10.012
  5. Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation vol.14, pp.1, 2014, https://doi.org/10.3892/ol.2017.6117
  6. Heating Preciosity—Trends in Modern Oncological Hyperthermia vol.7, pp.3, 2014, https://doi.org/10.4236/ojbiphy.2017.73010
  7. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two vol.7, pp.11, 2014, https://doi.org/10.1136/bmjopen-2017-017387
  8. Successful Outcome of an Elderly Patient with Small Cell Lung Cancer with only Alternative Treatments: A Case Report vol.39, pp.4, 2014, https://doi.org/10.13048/jkm.18043
  9. Modulated electro-hyperthermia-enhanced liposomal drug uptake by cancer cells vol.14, pp.None, 2019, https://doi.org/10.2147/ijn.s188791
  10. Bioelectromagnetic Paradigm of Cancer Treatment-Modulated Electro-Hyperthermia (mEHT) vol.9, pp.2, 2014, https://doi.org/10.4236/ojbiphy.2019.92008
  11. Oncological hyperthermia: The correct dosing in clinical applications vol.54, pp.2, 2014, https://doi.org/10.3892/ijo.2018.4645
  12. The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial vol.14, pp.6, 2019, https://doi.org/10.1371/journal.pone.0217894
  13. Presence of Gold Nanoparticles in Cells Associated with the Cell-Killing Effect of Modulated Electro-Hyperthermia vol.2, pp.8, 2014, https://doi.org/10.1021/acsabm.9b00453
  14. Radiotherapy in combination with hyperthermia suppresses lung cancer progression via increased NR4A3 and KLF11 expression vol.95, pp.12, 2014, https://doi.org/10.1080/09553002.2019.1665213
  15. Parametrization of Survival Measures (Part III) Clinical Evidences in Single Arm Studies with Endpoint of Overall Survival vol.11, pp.6, 2020, https://doi.org/10.4236/ijcm.2020.116034
  16. Modulated Electrohyperthermia: A New Hope for Cancer Patients vol.2020, pp.None, 2014, https://doi.org/10.1155/2020/8814878
  17. “Oncothermia” (Modulated electro-hyperthermia) : - Present status and future development - vol.37, pp.1, 2014, https://doi.org/10.3191/thermalmed.37.1